Immuron Reports 1H 2026 Financial Results and Announces a Strategic Reset. Immuron reported solid revenue growth for the first half of its 2026 fiscal year, ended December 31, 2025. Global sales were AUD $4.2 million, a 5% increase over 1H FY2025 revenue. Looking ahead, we expect continued commercial momentum in the U.S. and Australia, following the launch of the Company’s latest product, ProIBS®, in December 2025. During 1H 2026, Immuron raised AUD $7.3 million, bringing available cash to AUD $10.0 million. With a cash runway into 2027, the Company can now focus on clinical development of its two lead clinical product candidates.
